{"schema_version":"secwatch.filing_event.v1","accession":"0000885725-24-000040","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2024-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.301781+00:00","generated_at":"2026-06-03T10:52:58.501553+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Boston Scientific Q1 beats: $3.856B sales +13.8%, adj EPS $0.56 vs $0.50-0.52 guide; raises FY outlook","bullets":["GAAP net income $495M ($0.33 EPS) vs guide $0.29-0.31; adjusted EPS $0.56 vs $0.47 YoY and $0.50-0.52 guide.","Net sales $3.856B, +13.8% reported (guide 7.5-9.5%), +15.0% operational, +13.1% organic (guide 7-9%).","Cardiovascular +15.9% reported, MedSurg +10.3%; U.S. +12.7%, APAC +18.3%, Emerging Markets +22.6%.","Launched FARAPULSE PFA in U.S.; FDA approved AGENT Drug-Coated Balloon; €2.0B notes for Axonics acquisition.","FY2024 guidance: sales growth 11-13% reported, 10-12% organic; adj EPS $2.29-2.34; Q2 adj EPS $0.57-0.59."],"urls":{"canonical":"https://secwatch.observer/filing/0000885725-24-000040","json":"https://secwatch.observer/filing/0000885725-24-000040.json","markdown":"https://secwatch.observer/filing/0000885725-24-000040.md","text":"https://secwatch.observer/filing/0000885725-24-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000040/0000885725-24-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000040/bsx-20240424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T10:52:58.501553+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03fae87d2bd2f5ce08000bfa5fe33cc863a17cb4","claim":"BOSTON SCIENTIFIC CORP reported the first quarter ended March 31, 2024 results: revenue $3.856 billion, net income $495 million or $0.33 per share, EPS $0.56 for the period.","evidence_excerpt":"Document Boston Scientific Announces Results for First Quarter 2024 Marlborough, Mass. (April 24, 2024) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational 1 basis and 13.1 percent on an organic 2 basis, all compared to the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000040/0000885725-24-000040-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$3.856 billion"},{"label":"Net income","value":"$495 million or $0.33 per share"},{"label":"EPS","value":"$0.56 for the period"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}